Trial Profile
A Non-Randomized Phase Ib-II Protocol of Paclitaxel, Carboplatin and the Dual PI3K/mTOR Kinase Inhibitor, PF-05212384, for Patients With Advanced, or Metastatic Non-Small Cell Carcinoma of the Lung
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Gedatolisib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms UF-STO-LUNG-002
- 09 Sep 2019 Status changed from active, no longer recruiting to discontinued.
- 17 Jan 2019 Planned End Date changed from 30 Sep 2022 to 1 Feb 2020.
- 17 Jan 2019 Status changed from recruiting to active, no longer recruiting.